High affinity small molecule C5a receptor modulators

Details High affinity small molecule C5a receptor modulators High affinity small molecule C5a receptor modulators

2007-09-18

2007-09-18

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S311100

Reexamination Certificate

active

10853731

ABSTRACT:
This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations.This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

REFERENCES:
patent: 5159083 (1992-10-01), Thurkauf et al.
patent: 5428164 (1995-06-01), Thurkauf et al.
patent: 5478934 (1995-12-01), Yuan et al.
patent: 5633376 (1997-05-01), Thurkauf et al.
patent: 5633377 (1997-05-01), Thurkauf et al.
patent: 5646280 (1997-07-01), Thurkauf et al.
patent: 5681956 (1997-10-01), Thurkauf et al.
patent: 6723743 (2004-04-01), Thurkauf et al.
patent: 6884815 (2005-04-01), Thurkauf et al.
patent: WO 02/14265 (2002-02-01), None
Database CA on STN, (Columbus, OH, USA), No. 128:3703, Thurkauf, et al. ‘Preparation of 4-aryl substituted piperazinylmethylphenyl imidazoles as a new class of dopamine receptor subtype specific ligands’, abstract, Oct. 28, 1997.
Database CA on STN, (Columbus, OH, USA), No. 123:55767, Thurkauf, et al. ‘2-Phenyl-4-(aminomethyl)imidazoles as potential antipsychotic agents. Synthesis and dopamine D2 receptor binding,’ abstract, J. Med. Chem., vol. 38, No. 12, pp. 2251-2255, 1995.
Database CA on STN, (Columbus, OH, USA), No. 117: 2513500350, Thurkauf, etal., ‘Preparation of (aminomethyl)phenylimidazoles as dopamine receptor ligands,’ abstract, Jul. 23, 1992.
Database CA on STN, (Columbus, OH, USA), No. 105:191381, Shiga, et al., ‘Silane derivatives,’ abstract, Mar. 24, 1986.
Database CA on STN, (Columbus, OH, USA), No. 131:257737, He, et al., ‘Enantioselective total synthesis of aspidophytine,’ abstract, J. Am. Chem. Soc., vol. 121, No. 28, pp. 6771-6772, 1999.
Drug Report for “C5a antagonists”, Merck & Co., from the Investigational Drugs database, search done Feb. 18, 2002, last update Apr. 17, 2001. Summary, 1 page.
de Laszlo et al., “A Nonpeptide Agonist Ligand of the Human C5A Receptor: Synthesis, Binding Affinity Optimization and Functional Characterization,”Bioorganic&Medicinal Chemistry Lettersvol. 7, No. 2 pp. 213-218 and pp. 907-912 (1997).
Shilcrat, et al, “A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazoles and its Application to the Development of Eprosartan”, J. Org. Chem. 1997, 62, pp. 8449-8454.

Affiliated with

Also associated with

Rating

High affinity small molecule C5a receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High affinity small molecule C5a receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity small molecule C5a receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3780519